Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06488261 · ClinicalTrials.gov registry record
Long Term Follow-Up for Safety of AVR-RD-02
A clinical trial of Gaucher Disease, sponsored by John Bernat.
- Active
- Registry status
- 2
- Enrollment target
- 1
- Study location
NCT06488261: Active study of Gaucher Disease, sponsored by John Bernat.
NCT06488261 is a study of Gaucher Disease that is active but no longer recruiting, run by John Bernat. The registered enrollment target is 2 participants, below the 1,058-participant average among 13 other Gaucher Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06488261, a study of Gaucher Disease, is active but no longer recruiting, sponsored by John Bernat.
- ACTIVE NOT RECRUITING
- Registry status
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to assess the safety and tolerability of AVR-RD-02 treatment in subjects who previously received AVR-RD-02 treatment (single dose administration).
Conditions Studied
Interventions
- BIOLOGICAL AVR-RD-02
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-02-21 |
| Est. Completion | 2037-10 |
What the registry record for NCT06488261 still lists
NCT06488261 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,058-participant average among 13 other Gaucher Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Gaucher Disease appearing as the primary indexed condition, and to 1 intervention - of which AVR-RD-02 is the first listed.
NCT06488261 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT06488261 about?
NCT06488261 is a clinical study titled "Long Term Follow-Up for Safety of AVR-RD-02". The goal of this observational study is to assess the safety and tolerability of AVR-RD-02 treatment in subjects who previously received AVR-RD-02 treatment (single dose administration).
What is the current status of trial NCT06488261?
This trial is currently active not recruiting. The enrollment target is 2 participants. The study started on 2024-02-21. Estimated completion is 2037-10.
What conditions does trial NCT06488261 study?
This clinical trial studies the following conditions: Gaucher Disease.
What interventions are being tested in trial NCT06488261?
The interventions under investigation include: AVR-RD-02 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06488261?
This trial is sponsored by John Bernat, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06488261 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gaucher Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06488261's enrollment target sits among peer trials
2 14th of 13 the lowest of 13 other Gaucher Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gaucher Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease
RECRUITING
-
A Long-term Follow-up Study of Gaucher Disease
RECRUITING
-
Gaucher Disease Outcome Survey (GOS)
RECRUITING
-
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
RECRUITING
-
The GBA Multimodal Study in Parkinson's Disease
RECRUITING
-
Drug Discovery for Parkinson's With Mutations in the GBA Gene
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI